1. In Vivo
  2. >>Leadership

J&J Leans Into The Patient Opportunity In Vision

EMEA Vision Regional President Underlines Determination To Provide End-to-End Patient Care

 
• By Ashley Yeo

Jacqueline Henderson was appointed president, Johnson & Johnson Vision, EMEA, in April, as part of a restructuring of senior regional roles. Now overseeing this most culturally diverse of territories for both Vision Care and Surgical Vision, she explains the rationale for the internal realignment and where Johnson & Johnson Vision goes next.

Shutterstock

Jacqueline Henderson has held a variety of roles at Johnson & Johnson in a career that began in 1996 in consumer division sales in Canada. In April 2023, she was elevated from VP, EMEA, vision care, to president, Johnson & Johnson Vision EMEA, a newly created role conferring oversight of both Vision Care and Surgical Vision.

Hers was one of four regional president postings at the time, alongside those of Lori Tierney (Americas), Jun Morimura (Japan)...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Leadership

Surgical Robotics CEOs Talk Metrics For Success, Valuations And Competition

 
• By Marion Webb

Leaders of robotic systems companies Distalmotion, Neocis and Noah Medical discussed success metrics, competition and funding. Institutional investors are focusing on utilization, procedure rates and a clear path to profitability as the IPO window reopens, BTIG analyst Ryan Zimmerman said.

‘A Small Medtech Industry Ecosystem With An Outsized Global Influence’

 
• By Ashley Yeo

Entrepreneurialism is in the blood of Israel’s medtech innovators, but in a changing medtech world, the local ecosystem must address funding gaps and manufacturing and infrastructure needs. So says Ruti Alon, experienced Israeli medtech leader, investor and co-chair of the Biomed Israel conference.

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

More from In Vivo

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.